natgillin/translations-raw huggingface dataset:
Rivastigmine Teva 1.5 mg hard capsules Rivastigmine
Rivastigmine Teva 1,5 mg trde kapsule rivastigmin
Rivastigmine Teva 1.5 mg hard capsules Rivastigmine Teva 3 mg hard capsules Rivastigmine Teva 4.5 mg hard capsules Rivastigmine Teva 6 mg hard capsules
Rivastigmine Teva 1,5 mg trde kapsule Rivastigmine Teva 3 mg trde kapsule Rivastigmine Teva 4,5 mg trde kapsule Rivastigmine Teva 6 mg trde kapsule
Rivastigmine Teva 1.5 mg hard capsules: White cap imprinted with “R” & white body imprinted with “1.5”
Rivastigmine Teva 1,5 mg trde kapsule: bela kapa z natisnjenim napisom »R« in belo telo z natisnjenim napisom »1.5«.
Rivastigmine Teva 3 mg hard capsules
Rivastigmine Teva 3 mg trde kapsule
Rivastigmine Teva 3 mg hard capsules Rivastigmine
Rivastigmine Teva 3 mg trde kapsule rivastigmin
Rivastigmine Teva 3 mg hard capsules: Flesh colour cap imprinted with “R” & flesh colour body imprinted with “3”
Rivastigmine Teva 3 mg trde kapsule: kapa svetlo rjave barve z natisnjenim napisom »R« in telo svetlo rjave barve z natisnjenim napisom »3«.
Rivastigmine Teva 4.5 mg hard capsules
Rivastigmine Teva 4,5 mg trde kapsule
Rivastigmine Teva 4.5 mg hard capsules Rivastigmine
Rivastigmine Teva 4,5 mg trde kapsule rivastigmin
Rivastigmine Teva 4.5 mg hard capsules: Orange colour cap imprinted with “R” & orange colour body imprinted with “4.5”
Rivastigmine Teva 4,5 mg trde kapsule: kapa oranžne barve z natisnjenim napisom »R« in telo oranžne barve z natisnjenim napisom »4,5«.
Rivastigmine Teva 6 mg hard capsules
Rivastigmine Teva 6 mg trde kapsule
Rivastigmine Teva 6 mg hard capsules Rivastigmine
Rivastigmine Teva 6 mg trde kapsule rivastigmin
Rivastigmine Teva 6 mg hard capsules: Orange cap imprinted with “R” & flesh colour body imprinted with “6”
Rivastigmine Teva 6 mg trde kapsule: kapa oranžne barve z natisnjenim napisom »R« in telo svetlo rjave barve z natisnjenim napisom »6«.
Rivastigmine Teva allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Teva z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
Rivastigmine Teva can also be used to treat mild to moderately severe dementia in patients with Parkinson’s disease.
Zdravilo Rivastigmine Teva se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s parkinsonovo boleznijo.
Rivastigmine Teva is a ‘generic medicine’.
Rivastigmine Teva je „generično zdravilo“.
Rivastigmine Teva is used for the treatment of memory disorders in patients with Alzheimer’s disease.
Zdravilo Rivastigmine Teva se uporablja za zdravljenje spominskih motenj pri bolnikih z Alzheimerjevo boleznijo.
Rivastigmine Teva is used for the treatment of patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Zdravilo Rivastigmine Teva se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
Rivastigmine Teva might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).
Zdravilo Rivastigmine Teva lahko vpliva na delovanje antiholinergičnih zdravil (zdravil, ki se uporabljajo za lajšanje želodčnih krčev ali spazmov, za zdravljenje Parkinsonove bolezni ali za preprečevanje potovalne bolezni).
Rivastigmine transdermal patches
Rivastigmin transdermalni obliži
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose 104 times the maximum clinical exposure.
V skupini standardnih testov in vitro in in vivo rivastigmin ni bil mutagen, razen v testu kromosomskih aberacij v človeških perifernih levkocitih v odmerku, ki je bil za 104-krat večji od največje klinične izpostavljenosti.
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose exceeding 104 times the foreseen clinical exposure.
V standardni bateriji testov in vitro in in vivo rivastigmin ni bil mutagen, razen v testu kromosomskih aberacij v človeških perifernih levkocitih v odmerku, ki je 104-krat presegal dotedanjo klinično izpostavljenost.
RIXUBIS 1000 IU powder and solvent for solution for injection
RIXUBIS 1000 i.e. prašek in vehikel za raztopino za injiciranje
RIXUBIS 1000 IU powder and solvent for solution for injection Nonacog gamma (recombinant human coagulation factor IX)
RIXUBIS 1000 i.e. prašek in vehikel za raztopino za injiciranje Nonakog gama (rekombinantni humani koagulacijski faktor IX)
RIXUBIS 2000 IU powder and solvent for solution for injection
RIXUBIS 2000 i.e. prašek in vehikel za raztopino za injiciranje
RIXUBIS 2000 IU powder and solvent for solution for injection Nonacog gamma (recombinant human coagulation factor IX)
RIXUBIS 2000 i.e. prašek in vehikel za raztopino za injiciranje Nonakog gama (rekombinantni humani koagulacijski faktor IX)
RIXUBIS 250 IU powder and solvent for solution for injection Nonacog gamma (recombinant human coagulation factor IX)
RIXUBIS 250 i.e. prašek in vehikel za raztopino za injiciranje Nonakog gama (rekombinantni humani koagulacijski faktor IX)
RIXUBIS 3000 IU powder and solvent for solution for injection
RIXUBIS 3000 i.e. prašek in vehikel za raztopino za injiciranje
RIXUBIS 3000 IU powder and solvent for solution for injection Nonacog gamma (recombinant human coagulation factor IX)
RIXUBIS 3000 i.e. prašek in vehikel za raztopino za injiciranje Nonakog gama (rekombinantni humani koagulacijski faktor IX)
RIXUBIS 500 IU powder and solvent for solution for injection
RIXUBIS 500 i.e. prašek in vehikel za raztopino za injiciranje
RIXUBIS 500 IU powder and solvent for solution for injection Nonacog gamma (recombinant human coagulation factor IX)
RIXUBIS 500 i.e. prašek in vehikel za raztopino za injiciranje Nonakog gama (rekombinantni humani koagulacijski faktor IX)
RIXUBIS contains sodium
Zdravilo RIXUBIS vsebuje natrij.
RIXUBIS contains the active substance nonacog gamma and is a coagulation factor IX product.
Zdravilo RIXUBIS vsebuje zdravilno učinkovino nonakog alfa in je pripravek koagulacijskega faktorja IX.
RIXUBIS is administered by intravenous infusion (IV) after reconstitution of the powder with the provided solvent by your doctor or nurse.
Zdravilo RIXUBIS se daje z intravensko infuzijo (i.v.) po rekonstituciji praška s priloženim vehiklom, kar opravi zdravnik ali medicinska sestra.
ro ro
ni
RoActemra 162 mg solution for injection in pre-filled syringe
RoActemra 162 mg raztopina za injiciranje v napolnjeni injekcijski brizgi tocilizumab
RoActemra 162 mg solution for injection in pre-filled syringe Tocilizumab
RoActemra 162 mg raztopina za injiciranje v napolnjeni injekcijski brizgi tocilizumab
RoActemra 162 mg solution for injection in pre-filled syringe.
RoActemra 162 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
RoActemra 20 mg/ml concentrate for solution for infusion
RoActemra 20 mg/ml koncentrat za raztopino za infundiranje tocilizumab
RoActemra 20 mg/ml concentrate for solution for infusion Tocilizumab
RoActemra 20 mg/ml koncentrat za raztopino za infundiranje tocilizumab
RoActemra 20 mg/ml concentrate for solution for infusion.
RoActemra 20 mg/ml koncentrat za raztopino za infundiranje
RoActemra can affect the way some medicines work, and the dose of these may require adjustment.
Zdravilo RoActemra lahko vpliva na delovanje nekaterih zdravil in morda bo treba njihove odmerke prilagoditi.
RoActemra can also be used to treat adults who have not had previous methotrexate treatment if they have severe, active and progressive rheumatoid arthritis.
Zdravilo RoActemra se lahko uporablja tudi za zdravljenje odraslih bolnikov s hudim, aktivnim in napredujočim revmatoidnim artritisom brez predhodnega zdravljenja z metotreksatom.
RoActemra can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of rheumatoid arthritis, active systemic juvenile idiopathic arthritis or juvenile idiopathic polyarthritis.
Predpisovanje in izdaja zdravila je le na recept in zdravljenje lahko uvede le zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa, aktivnega sistemskega juvenilnega idiopatskega artritisa ali juvenilnega idiopatskega poliartritisa.
RoActemra can reduce your body’s ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection.
Zdravilo RoActemra lahko zmanjša sposobnost telesa za odziv na okužbe ter lahko poslabša obstoječo okužbo ali poveča možnost za pojav nove okužbe.
RoActemra contains sodium
Zdravilo RoActemra vsebuje natrij
RoActemra contains the active substance tocilizumab, which is a protein made from specific immune cells (monoclonal antibody), that blocks the action of a specific protein (cytokine) called interleukin-6.
Zdravilo RoActemra vsebuje zdravilno učinkovino tocilizumab, ki je beljakovina, narejena iz specifičnih imunskih celic (monoklonsko protitelo), ki blokira delovanje posebne beljakovine (citokina), imenovane interlevkin-6.
RoActemra contains the active substance tocilizumab.
Vsebuje zdravilno učinkovino tocilizumab.
RoActemra given by injection under the skin has been investigated in two studies involving 1,918 patients with moderate to severe rheumatoid arthritis where previous treatment with DMARD had not worked well.
Zdravilo RoActemra, ki se injicira pod kožo, so raziskovali tudi v dveh študijah, pri katerih je sodelovalo 1 918 bolnikov z zmernim ali hudim revmatoidnim artritisom, pri katerih predhodno zdravljenje z imunomodulirajočim antirevmatičnim zdravilom (DMARD) ni bilo učinkovito.
RoActemra has a minor influence on the ability to drive and use machines (see section 4.8, dizziness).
Zdravilo RoActemra ima blag vpliv na sposobnost vožnje in upravljanja s stroji (glejte poglavje 4.8, omotica).
RoActemra has minor influence on the ability to drive and use machines (see section 4.8, dizziness).
Zdravilo RoActemra ima blag vpliv na sposobnost vožnje in upravljanja s stroji (glejte poglavje 4.8, omotica).
RoActemra helps to reduce symptoms such as pain and swelling in your joints and can also improve your performance of daily tasks.
Zdravilo RoActemra pomaga olajšati simptome, npr. bolečine in oteklost sklepov, in lahko tudi izboljša vašo sposobnost za vsakodnevna opravila.
RoActemra is a concentrate for solution for infusion.
Zdravilo RoActemra je koncentrat za raztopino za infundiranje.
RoActemra is a medicine used to treat rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults with:
Zdravilo RoActemra se uporablja za zdravljenje revmatoidnega artritisa (bolezni imunskega sistema, ki povzroča vnetje sklepov) pri odraslih:
RoActemra is a solution for injection.
Zdravilo RoActemra je v obliki raztopine za injiciranje.
RoActemra is also used in children from 2 years of age to treat two childhood arthritis conditions, active systemic juvenile idiopathic arthritis and juvenile idiopathic polyarthritis, in patients who have not responded to other treatments (NSAIDs and corticosteroids).
Zdravilo RoActemra se uporablja tudi za zdravljenje dveh otroških artritičnih bolezni (aktivnega sistemskega juvenilnega idiopatskega artritisa in juvenilnega idiopatskega poliartritisa) pri bolnikih, ki se niso odzvali na druge vrste zdravljenja (z nesteroidnimi protivnetnimi zdravili in kortikosteroidi).
RoActemra is not recommended for use in children under 2 years of age.
Zdravila RoActemra ni priporočljivo uporabljati pri otrocih, mlajših od 2 let.
RoActemra is not to be used in pregnancy unless clearly necessary.
Zdravila RoActemra ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
RoActemra is supplied as a 0.9 ml pre-filled syringe containing 162 mg tocilizumab solution for injection.
Zdravilo RoActemra je na voljo v napolnjeni injekcijski brizgi, ki vsebuje 162 mg tocilizumaba v 0,9 ml raztopine za injiciranje.
RoActemra is supplied as vials containing 4 ml, 10 ml and 20 ml concentrate for solution for infusion.
Zdravilo RoActemra je na voljo v vialah po 4, 10 ali 20 ml koncentrata za raztopino za infundiranje.
RoActemra is used to treat adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, if previous therapies did not work well enough.
Zdravilo RoActemra se uporablja za zdravljenje odraslih bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom (avtoimunsko boleznijo), če predhodna zdravljenja niso učinkovala dovolj dobro.
RoActemra is used to treat children with pJIA.
Zdravilo RoActemra se uporablja tudi za zdravljenje otrok s pJIA.
RoActemra is used to treat children with sJIA.
Zdravilo RoActemra se uporablja za zdravljenje otrok s sJIA.
RoActemra is usually given in combination with methotrexate.
Zdravilo RoActemra se po navadi uporablja v kombinaciji z metotreksatom.
RoActemra is usually used in combination with methotrexate but can be used on its own in patients for whom methotrexate is inappropriate.
Uporablja se skupaj z metotreksatom, vendar se lahko pri bolnikih, za katere metotreksat ni primeren, uporablja samostojno.
RoActemra should be diluted to a final volume of 100 ml with sterile, non-pyrogenic sodium chloride 9 mg/ml (0.9%) solution for injection using aseptic technique.
Zdravilo RoActemra je treba razredčiti na končni volumen 100 ml s sterilno, apirogeno 0,9 % (9 mg/ml) raztopino natrijevega klorida za injiciranje upoštevaje aseptičen postopek.
RoActemra subcutaneous injection is not recommended for use in children under 18 years of age.
Zdravila RoActemra v subkutani injekciji ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
RoActemra, in combination with methotrexate (MTX), is indicated for
Zdravilo RoActemra je v kombinaciji z metotreksatom indicirano za zdravljenje:
RoActemra, in combination with methotrexate (MTX), is indicated for:
Zdravilo RoActemra je v kombinaciji z metotreksatom indicirano za zdravljenje:
RoActemra, on its own or in combination with methotrexate, was compared with placebo (a dummy treatment) plus methotrexate.
Zdravilo RoActemra, ki so ga bolniki prejemali samostojno ali v kombinaciji z metotreksatom, so primerjali s placebom (zdravilom brez zdravilne učinkovine) ob sočasnem jemanju metotreksata.
Robenacoxib had analgesic and anti-inflammatory actions in an inflammation model in dogs with single oral doses ranging from 0.5 to 8 mg/kg, with an ID50 of 0.8 mg/kg and a rapid onset of action (0.5 h).
Pri vnetnem modelu pri psih so enkratni peroralni odmerki robenakoksiba od 0,5 do 8 mg/kg telesne mase z ID50 0,8 mg/kg učinkovali hitro protibolečinsko in protivnetno (0,5 h).
Robenacoxib has a relatively small volume of distribution (Vss 190 ml/kg) and is highly bound to plasma proteins (>99%).
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 190 ml/kg) in se zelo dobro veže na plazemske proteine (> 99 %).
Robenacoxib has a relatively small volume of distribution (Vss 240 ml/kg) and is highly bound to plasma proteins (>99%).
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 240 ml/kg) in se zelo dobro veže na plazemske proteine (> 99 %).
Robenacoxib has a relatively small volume of distribution (Vss of 190 ml/kg in cats and 240 ml/kg in dogs) and is highly bound to plasma proteins (>99%).
Robenakoksib ima razmeroma majhno prostornino porazdelitve (Vss 190 ml/kg pri mačkah in Vss 240 ml/kg pri psih) in se zelo dobro veže na plazemske proteine (> 99 %).
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class.
Robenakoksib je nesteroidno antirevmatično zdravilo (NSAID) iz skupine koksibov.
Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID).
Robenakoksib je nesteroidno antirevmatično zdravilo (NSAID).
Robenacoxib is cleared rapidly from blood (CL 0.81 L/kg/h) with an elimination t1/2 of 0.7 h after intravenous administration.
Robenakoksib se po intravenozni aplikaciji iz krvi izloča hitro, njegov plazemski očistek je CL 0,81 l/kg/h, razpolovni čas pa t1/2 0,7 h.
Robenacoxib is excreted predominantly via the biliary route (65%) and the remainder via the kidneys.
Pretežno se izloča z žolčem ( 65 %), preostali del pa preko ledvic.
Robenacoxib is excreted predominantly via the biliary route (70%) rather than via the kidneys (30%).
Pretežno se izloča z žolčem ( 70 %), v približno 30 % pa preko ledvic.
Robenacoxib is excreted predominantly via the biliary route in cats (70%) and dogs (65%) and the remainder via the kidneys.
Pretežno se izloča z žolčem tako pri mačkah ( 70 %) kot pri psih ( 65 %), preostali del pa preko ledvic.
Robenacoxib is extensively metabolised by the liver in cats and dogs.
Robenakoksib se pri mačkah in psih presnavlja večinoma v jetrih.
Robenacoxib is extensively metabolised by the liver in dogs.
Robenakoksib se pri psih presnavlja večinoma v jetrih.
Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood.
Na vnetnih mestih ostaja robenakoksib dlje časa in v višjih koncentracijah kot v krvi.
Robert-Bosch-Strasse 8 D – 78224 Singen Germany
Robert-Bosch-Strasse 8 D – 78224 Singen Nemčija
Robust evidence for benefit on this outcome parameter could not be demonstrated for ‘immediate’ treatment.
Robustnosti dokaza koristnosti učinka na ta parameter ni bilo mogoče prikazati za "takojšnje" zdravljenje.
Roche Latvija SIA Tel: +371 -6 7039831
Roche Latvija SIA Tel: +371 - 6 7 039831
Roche Pharma AG Emil-Barell-Strasse 1
Roche Pharma AG Emil-Barell-Strasse-1
Roche Pharma AG Emil-Barrell-Str.
Roche Pharma AG Emil-Barell-Str.
Roche Pharma AG Emil-Barrell-Str.
Roche Pharma AG Emil-Barell-Str.1,
Roche Pharma AG, Emil-Barell-Strasse 1,
Roche Pharma AG Emil-Barell- Strasse 1
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, Velika Britanija
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.
Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, Velika Britanija
Rockville, MD 20850 USA
Rockville, MD 20850 ZDA
Rocuronium and sugammadex (16 mg/kg)
rokuronij in sugamadeks (16 mg/kg)
Rocuronium and sugammadex (2 mg/kg)
rokuronij in sugamadeks (2 mg/kg)
Roflumilast (N=969)
Roflumilas t (N=969)
roflumilast treated COPD patients compared with COPD patients not
roflumilastom, v primerjavi z bolniki s KOPB, ki se ne zdravijo z
Roll the cartridge between your palms 10 times – it is important that the cartridge is kept horizontal (level with the ground) (see picture A).
Zavrtite injekcijski vložek 10-krat med dlanmi – pomembno je, da injekcijski vložek držite vodoravno (vzporedno s tlemi) (glejte sliko A).
Roll the pen between your palms 10 times – it is important that the pen is kept horizontal (level with the ground).
Injekcijski peresnik 10-krat zavrtite med dlanmi – pomembno je, da ga držite vodoravno (vzporedno s tlemi).
Romania/ România
Romunija/România
Romiplostim is a protein that has been ‘engineered’ (specifically designed) so that it can attach to and stimulate the same receptors as thrombopoietin.
Romiplostim je beljakovina, ki je bila posebej zasnovana, da se lahko veže na iste receptorje kot trombopoetin in jih spodbuja.
Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production.
Romiplostim je Fc-peptidna fuzijska beljakovina (peptidno telo), ki signalizira in aktivira znotrajcelične transkripcijske poti preko receptorjev TPO (te receptorje imenujemo tudi cMpI), in tako poveča nastajanje trombocitov.
Romiplostim was administered to 157 subjects by subcutaneous (SC) injection once weekly starting at a dose of 3 µg/kg, and adjusted throughout the study within a range of 1-10 µg/kg in order to maintain platelet counts between 50 and 200 x 109/l, 77 subjects received SOC treatment according to standard institutional practice or therapeutic guidelines.
157 bolnikom v subkutani (s.c.) injekciji enkrat na teden, uvodoma v odmerku 3 µg/kg in s prilagajanjem med celotno študijo v razponu 1-10 µg/kg, tako da so število trombocitov vzdrževali med 50 in 200 x 109/l, 77 bolnikov pa je prejelo standardno zdravstveno oskrbo v skladu z običajno prakso ustanove ali s terapevtskimi smernicami.
România
333
România
Malta
România sanofi - aventis Romania SRL Tel.: +40(21) 317 31 36
România sanofi – aventis Romania SRL Tel.: +40(21) 317 31 36
Room spinning sensation and vision disturbances may occur after taking Humira.
Po dajanju zdravila Humira se lahko pojavita vrtoglavica in poslabšanje vida.
ROS1-Positive Advanced NSCLC
ROS1-pozitvni napredovali NSCLC
ROS1-positive advanced NSCLC efficacy results from Study 1001
Rezultati o učinkovitosti zdravljenja ROS1-pozitivnega napredovalega NSCLC iz Študije 1001
Rosacea (facial redness), rosacea-like dermatitis, lentigo (presence of flat brown spots on the skin), oedema at the application site and herpes eye infections have been reported during post-marketing experience.
Med nadzorom zdravila po začetku njegovega trženja so poročali tudi o rozacei (pordelost obraza), rozacei podobnem vnetju kože (dermatitisu), lentigu (prisotnost ploščatih rjavih lis na koži), otekanju kože na mestu uporabe in okužbah oči z virusom herpes.
Rosacea (facial redness), rosacea-like dermatitis, lentigo (presence of flat brown spots on the skin), oedema at the application site and herpes eye infections have been reported during post-marketing experience.
Med postmarketinškim nadzorom so poročali tudi o rozacei (pordelost obraza), rozacei podobnem vnetju kože (dermatitisu), lentigu (prisotnost ploščatih rjavih lis na koži), otekanju kože na mestu uporabe in okužbah oči z virusom herpes.
rosacea (redness of the face)
rozacea (pordelost obraza)
Rosacea and rosacea-like dermatitis have also been reported.
Opazili so tudi rozaceo in rozaceji podobno vnetje kože.
Rosacea* Lentigo*
Rozacea* Lentigo
Rosacea, seborrheic dermatitis, skin neoplasm, maculopapular rash, skin cysts, vesiculobullous rash, skin disorder, hirsutism, skin tightness
rozacea, seboroični dermatitis, kožni rak, makulopapulozni izpuščaj, kožne ciste, vezikulobulozni izpuščaj, bolezni kože, hirsuitizem, napetost kože
Rose
roza
Rosiglitazone 4 mg/day
rosiglitazon 4 mg/dan
Rosiglitazone and glimepiride work together so your body makes better use of the insulin it produces, and this helps reduce your blood sugar to a normal level.
Rosiglitazon in glimepirid delujeta skupaj tako, da omogočata boljšo izrabo v telesu nastalega insulina, kar pomaga zmanjšati vrednost krvnega sladkorja na normalno vrednost.
Rosiglitazone is a selective agonist at the PPAR (peroxisomal proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of anti-diabetic agents.
Rosiglitazon je selektiven agonist za jedrni receptor PPARγ (peroksisomalni receptor gama, ki ga aktivira proliferator) in sodi v tiazolidindionsko skupino antidiabetikov.
Rosiglitazone is a selective agonist at the PPAR (peroxisome proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of antihyperglycaemic agents.
Rosiglitazon je selektiven agonist jedrnih receptorjev PPARγ (peroksisomski proliferatorski aktivirani receptor gama) in spada med tiazolidindionske antihiperglikemike.
Rosiglitazone is a selective agonist at the PPAR (peroxisome proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of antihyperglycaemic agents.
Rosiglitazon je selektiven agonist jedrnih receptorjev PPAR (peroksisomski proliferatorski aktivirani receptor gama) in spada med tiazolidindionske antihiperglikemike.